Halozyme seeks to buy Evotec

Halozyme, a California firm that engineers under-the-skin injectable versions of intravenous drugs, is looking to buy the German pharmaceutical services company Evotec. Haloyzme says it offered to purchase Evotec for about $2.1 billion to create a services company that spans the US and Europe. Evotec says in a statement that it will “carefully analyze this expression of interest.” The firm has reportedly courted other potential buyers in recent weeks , including the private equity firm Triton Partners.